1Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
2Fava, M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649–59.
3Zarate, CA Jr, Singh, JB, Carlson, PJ, Brutsche, NE, Ameli, R, Luckenbaugh, DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856–64.
4Murrough, JW, Iosifescu, DV, Chang, LC, Al Jurdi, RK, Green, CE, Perez, AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134–42.
5Singh, JB, Fedgchin, M, Daly, EJ, De Boer, P, Cooper, K, Lim, P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 2016; 173: 816–26.
6Lapidus, KA, Levitch, CF, Perez, AM, Brallier, JW, Parides, MK, Soleimani, L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014; 76: 970–6.
7Lara, DR, Bisol, LW, Munari, LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013; 16: 2111–7.
8Galvez, V, O'Keefe, E, Cotiga, L, Leyden, J, Harper, S, Glue, P, et al. Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: a case report. Biol Psychiatry 2014; 76: e1–2.
9Peltoniemi, MA, Hagelberg, NM, Olkkola, KT, Saari, TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet 2016; 55: 1059–77.
10Iglewicz, A, Morrison, K, Nelesen, RA, Zhan, T, Iglewicz, B, Fairman, N, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics 2015; 56: 329–37.
11Jafarinia, M, Afarideh, M, Tafakhori, A, Arbabi, M, Ghajar, A, Noorbala, AA, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord 2016; 204: 1–8.
12Swiatek, KM, Jordan, K, Coffman, J. New use for an old drug: oral ketamine for treatment-resistant depression. BMJ Case Rep 2016; 2016: 216088.
13Al Shirawi, MI, Kennedy, SH, Ho, KT, Byrne, R, Downar, J. Oral ketamine in treatment-resistant depression: a clinical effectiveness case series. J Clin Psychopharmacol 2017; 37: 464–7.
14Schoevers, RA, Chaves, TV, Balukova, SM, Rot, MA, Kortekaas, R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 2016; 208: 108–13.
15Lecrubier, Y, Sheehan, DV, Weiller, E, Amorim, P, Bonora, I, Sheehan, K, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997; 5: 224–31.
16Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
17Zimmerman, M, Posternak, MA, Chelminski, I. Defining remission on the Montgomery-Asberg depression rating scale. J Clin Psychiatry 2004; 65: 163–8.
18Murrough, JW, Perez, AM, Pillemer, S, Stern, J, Parides, MK, aan het Rot, M, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250–6.
19Zimmerman, M, Posternak, MA, Chelminski, I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004; 38: 577–82.
20Crown, WH, Finkelstein, S, Berndt, ER, Ling, D, Poret, AW, Rush, AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002; 63: 963–71.
21Mrazek, DA, Hornberger, JC, Altar, CA, Degtiar, I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv 2014; 65: 977–87.
22Kornstein, SG, Schneider, RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001; 62 (suppl 16): 18–25.
23McIntyre, RS, Filteau, MJ, Martin, L, Patry, S, Carvalho, A, Cha, DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014; 156: 1–7.
24Ruhe, HG, van Rooijen, G, Spijker, J, Peeters, FP, Schene, AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord 2012; 137: 35–45.
25Daly, EJ, Singh, JB, Fedgchin, M, Cooper, K, Lim, P, Shelton, RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018; 75: 139–48.
26Grunebaum, MF, Galfalvy, HC, Choo, TH, Keilp, JG, Moitra, VK, Parris, MS, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry 2017: 175: 327–35.